An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the CAMN107A2109 study.
between 6 and 12 months
Colombia: Instituto Nacional De Vigilancia De Medicamentos y Alimentos